AI assistant
Cytek Biosciences, Inc. — Director's Dealing 2022
Oct 11, 2022
32966_dirs_2022-10-11_9c654924-f70f-4d0d-bc09-21f78d198ed9.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Cytek Biosciences, Inc. (CTKB)
CIK: 0001831915
Period of Report: 2022-10-07
Reporting Person: Jiang Wenbin (Director, President and CEO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-10-07 | Common Stock | S | 20000 | $14.79 | Disposed | 7805820 | Direct |
Footnotes
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 6, 2021.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.49 to $15.27, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.